论文部分内容阅读
口服疫苗能进入粘膜免疫系统,但易被消比和排泄,增大剂量又可引起免疫耐受性.用丙交酯和乙交酯构成的多聚体(PLG)微粒作为疫苗载体具有生物相容性,并能稳定包被的生物分子.用PLG包被抗原免疫小鼠可产生体液和细胞免疫,并预防嗣后的感染.本文研究了口服微囊化百日咳杆菌菌毛在小鼠中的免疫应答.作者以6～8周龄的NIH雌性小鼠为实验动物,免疫组小鼠分别按下列方案接受单剂10μg百日咳杆菌菌毛蛋白:(1)腹腔注射悬浮于0.5ml磷酸缓冲盐水(PBS)中的6mg PLG微粒;(2)腹腔注射悬浮于0.5mlPBS中的25%铝胶;(3)口饲悬浮于0.5ml NaHCO_3中的6mg PLG微粒.对照组小鼠分别接受:(1)口饲0.5ml含未包被菌毛的NaHCO_3溶液;(2)腹腔注射或口饲悬浮于PBS或NaHCO_3溶液中不含百日咳杆
Oral vaccine can enter the mucosal immune system, but easy to eliminate and excretion, increasing dose can cause immune tolerance.Lactylolide and glycolide multimer (PLG) particles as a vaccine carrier with a biological phase Capacitive and can stabilize the coated biomolecules.Immunization of mice with PLG-coated antigen can produce humoral and cellular immunity and prevent subsequent infection.In this paper, we studied the immunity of oral microencapsulated pertussis fimbriae in mice Response. The NIH female mice, 6-8 weeks of age, were used as experimental animals, and immunized mice received a single dose of 10 μg of pertactin per the following protocol: (1) intraperitoneally injected in 0.5 ml phosphate buffered saline (2) intraperitoneal injection of 25% aluminum colloid suspended in 0.5 ml PBS, (3) 6 mg PLG microparticles suspended in 0.5 ml NaHCO 3 in the mouth, mice in the control group received (1) oral Feeding 0.5ml containing non-coated pili hair NaHCO_3 solution; (2) intraperitoneal injection or oral suspended in PBS or NaHCO_3 solution does not contain pertussis rod